"Index" [2013] ELECD 856; in Drexl, Josef; Lee, Nari (eds), "Pharmaceutical Innovation, Competition and Patent Law" (Edward Elgar Publishing, 2013) 323

Book Title: Pharmaceutical Innovation, Competition and Patent Law

Editor(s): Drexl, Josef; Lee, Nari

Publisher: Edward Elgar Publishing

ISBN (hard cover): 9780857932457

Section Title: Index

Number of pages: 16

Extract:

Index
abbreviated new drug applications see switching facilitated by generic
ANDAs substitution 280­85
abortions 14, 21 tentative solution under Art 102
abridged applications 276­8 TFEU 285­9
abridged procedure 151, 277, 291­2, withdrawal of marketing
300­302 authorization for first generation
absolute protection 66, 76­7 product 276­8
abstract ideas 9, 29­30 antigens 211­13
abuses 262­6, 269­70, 277­8, 286­7, applications
289­99, 301­3, 318­20 abridged 276­8
abusive practices of protection 241­72 generic 127­8, 151, 153­4, 158­9,
acquisitions 136, 251, 258­9, 261­4 170, 173­4, 276
active ingredients 143­4, 195­200, industrial 58, 76, 80­82
204­5, 207­14, 223­6, 230­34, medical 59, 67, 144
236­8 patent see patent applications
active moiety 127, 130, 200­201 PCT 103­4
see also active ingredients SPC 295, 313
additional protection 160, 163, 165 appropriateness 195, 198, 312, 314, 318
administration 69, 101, 138, 140, 153, approvals 112­13, 119­20, 134­5,
183­4, 194 187­8, 190­91, 201­3, 220­35
routes 115, 135, 153, 156, 163 FDA 113­14, 116, 119, 122­3, 128,
administrative law 174, 222 132, 135
Alzheimer disease 18, 20, 217 first 191, 195, 200, 228, 231, 233
amino acids 8, 82, 89 marketing see marketing
ANDAs (abbreviated new drug authorization/approval
applications) 112, 115­17, 119, phase 122­3
127­8, 135, 186­7, 190 Pre-Hatch-Waxman 112­14
anti- ...